Multiple Myeloma

A brief overview of stem cell transplant’s role in the first-line treatment setting of newly diagnosed multiple myeloma.

Expert panelists review available induction therapy regimens for patients newly diagnosed with transplant-eligible multiple myeloma in the context of clinical data.

C. Ola Landgren, MD, recaps a recent panel discussion of the rapidly changing treatment landscape in multiple myeloma, and prospects for future development.

Findings from the phase 1/2 MajesTEC-1 trial suggest that preemptively planning and promptly managing cytokine release syndrome with supportive care in patients with multiple myeloma treated with T-cell–engaging bispecific antibodies may be beneficial.

Robert Mancini, PharmD, and Kiah Purcell, AGPCNP-B, discuss other targets for bispecific antibodies in multiple myeloma treatment and the infection patterns.

A brief review of bispecific antibody dosing strategies in multiple myeloma to improve patient outcomes and address concurrent adverse events.

Dr Robert Mancini summarizes the role of BCMA-targeted bispecific antibodies in multiple myeloma treatment and the side effects usually seen.

Expert panelists review the first patient case of multiple myeloma wherein cytokine release syndrome (CRS) develops during treatment with a BCMA-targeted bispecific antibody.

Switching its focus to non-BCMA-targeting therapies, a panel of experts consider the clinical data behind talquetamab in patients diagnosed with multiple myeloma,

Expert oncologists briefly review safety profiles of BCMA-targeted bispecifics in multiple myeloma and share practical insight on how to mitigate or address toxicities.

Shared insight on the respective roles of a multidisciplinary care team involved in the management of multiple myeloma and associated adverse events.

Shared insight on how experts select among the available BCMA-targeting bispecific antibodies and CAR T-cell therapies in patients with multiple myeloma.

Expert panelists reflect on other clinical trials aimed at defining the role for BCMA-targeting bispecifics in multiple myeloma and consider how they would utilize this class of agents in real-world practice.

James J. Driscoll, MD, PhD, and James Ignatz-Hoover, MD, PhD, share a perspective on a study published recently in ONCOLOGY.

Key opinion leaders in the field of multiple myeloma review clinical data behind BCMA-targeting bispecific antibody elranatamab, followed by other T-cell engagers in the pipeline.

Opening its discussion on BCMA-targeting bispecific antibodies in multiple myeloma, a panel of expert oncologists highlights key clinical data behind teclistamab.

Zhubin J. Gahvari, MD, MS, and Natalie S. Callander, MD, provide a comprehensive overview of current treatment paradigms in relapsed and refractory multiple myeloma.

Data from the phase 3 KarMMA-3 trial support several applications for idecabtagene vicleucel in earlier use for triple-class exposed multiple myeloma in the United States, Europe, and Japan.

OM-301, which demonstrated preclinical anti-cancer activity in multiple myeloma, receives orphan drug designation from the FDA.

Nora Biran, MD, and David Siegel, MD, offer closing remarks on the MM treatment landscape.

CB-011, which received fast track designation from the FDA, is currently under investigation as a treatment for those with relapsed or refractory multiple myeloma in the phase 1 CaMMouflage trial.

Investigators behind a phase 1 trial investigating MT-0169 in relapsed or refractory multiple myeloma and non-Hodgkin lymphoma will pause enrollment of new patients following prior reports of cardiac adverse effects in 2 patients.

Experts in the multiple myeloma space review available therapies such as CAR T-cell therapy, bispecifics, and B-cell maturation antigen–targeted agents for patients with multiple myeloma.

The panel closes their discussion with a look at an ongoing clinical trial in transplant-ineligible NDMM.

Dr Sandy Wong reviews data from a patient subgroup analysis of the MAIA trial in transplant-ineligible NDMM.

Ravi Vij, MD, MBA, and Luciano Costa, MD, face off over myeloma data from ASH 2022.

Myeloma experts share their thoughts on the future of multiple myeloma treatment.

Experts on multiple myeloma compare their treatment sequencing strategies.

Anne-Marie Jacob, a patient with multiple myeloma, discusses the treatment of multiple myeloma with bispecifics alongside a panel of experts.